Loading news...
Terumo Corp. (OTCMKTS:TRUMY - Get Free Report)'s share price gapped down before the market opened on Friday. The stock had previously closed at $12.76, but opened at $12.1501. Terumo shares last traded at $12.54, with a volume of 652 shares. Terumo Stock Down 0.8% The firm's 50-day moving average price is $13.96 and its
Terumo Corporation (TRUMY) Q3 2026 Earnings Call Transcript
Terumo Corporation (TRUMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Terumo (OTCMKTS:TRUMY - Get Free Report) and Utah Medical Products (NASDAQ: UTMD - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Insider and Institutional Ownership 69.6% of Utah Medical
TriSalus Life Sciences (NASDAQ: TLSI - Get Free Report) and Terumo (OTCMKTS:TRUMY - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation. Analyst Ratings This is a breakdown of recent
Terumo (OTCMKTS:TRUMY - Get Free Report) and BioLife Solutions (NASDAQ: BLFS - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Analyst Ratings This is a summary of recent ratings
Terumo (OTCMKTS:TRUMY - Get Free Report) and Brainsway (NASDAQ: BWAY - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Profitability This table compares Terumo and Brainsway's net margins, return
Terumo Corporation (OTCPK:TRUMY) Q2 2026 Earnings Call November 12, 2025 3:00 AM EST Company Participants Jin Hagimoto - CFO, CIO, GM of Accounting, Corporate Planning, Tax, IT Planning Dept. & GBS Hikaru Samejima - Representative Director, President & CEO Kojiro Otaka - General Manager of Corporate Planning Dept.
OXFORD, England and MADISON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd.
New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreement Terumo to pay a total of $30 million to Orchestra BioMed Orchestra BioMed retains all development and distribution rights to Virtue SAB in all indications Orchestra BioMed recently initiated patient enrollment for the Virtue Trial, its U.S. pivotal IDE trial of Virtue SAB in the treatment of coronary in-stent restenosis (“ISR”) NEW HOPE, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that it has entered into a termination and right of first refusal agreement (the “ROFR Agreement”) with Terumo Corporation (TYO:4543) and Terumo Medical Corporation (collectively, “Terumo”) with respect to Virtue® Sirolimus AngioInfusion™ Balloon (“SAB”) for the treatment of coronary artery disease worldwide.
Terumo Corporation (OTCPK:TRUMF) Q1 2026 Earnings Conference Call August 7, 2025 4:00 AM ET Company Participants Jin Hagimoto - CFO, CIO, GM of Accounting, Corporate Planning, Tax, IT Planning Dept. & GBS Kojiro Otaka - Corporate Participant Conference Call Participants Hidemaru Yamaguchi - Citigroup Inc., Research Division Motoya Kohtani - Mizuho Securities Co., Ltd.
Terumo continues to deliver solid financial results, with steady revenue growth and margin improvement, but share price performance has lagged the broader med-tech sector. The company's strengths lie in its established leadership in radial access products, strong BCT segment, and disciplined expansion into new growth areas like CDMO services. Management guides for healthy 7% constant currency growth and margin expansion, though U.S. tariffs could pose near-term profit headwinds.
Terumo Corporation (OTCPK:TRUMF) Q4 2025 Results Conference Call May 14, 2025 4:00 AM ET Company Participants Jin Hagimoto - Chief Financial Officer Hikaru Samejima - President & Chief Executive Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Tony Ren - Macquarie Ryotaro Hayashi - Morgan Stanley Tomoko Yoshihara - UBS Motoya Kohtani - Mizuho Securities Takahiro Mori - Nomura Securities Operator Thank you very much for taking the time to attend Terumo's Financial Results Presentation for the Fourth Quarter of 2025. So today, Mr.
Dublin, Feb. 24, 2025 (GLOBE NEWSWIRE) -- The "Balloon Catheters Patent Landscape Report" has been added to ResearchAndMarkets.com's offering.
Terumo Corporation (OTCPK:TRUMF) Q3 2025 Earnings Conference Call February 13, 2025 3:00 AM ET Company Participants Jin Hagimoto – Chief Financial Officer Conference Call Participants Jin Hagimoto [Call Starts Abruptly] Thank you for your kind introduction. I'm Hagimoto, Terumo's CFO.
Terumo Corporation (OTCPK:TRUMF) Q2 2025 Earnings Conference Call November 7, 2024 3:00 AM ET Company Participants Jin Hagimoto – Chief Financial Officer Hikaru Samejima – Chief Executive Officer Conference Call Participants Operator Please Hagimoto-san. Jin Hagimoto Yes, thank you very much for participating our earning calls today.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Terumo (TRUMY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Terumo (TRUMY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Terumo Corp. (TRUMY) have what it takes to be a top stock pick for momentum investors? Let's find out.